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At the conclusion of this session, the participant  
will be able to accomplish the following: 
 
 Describe the key components in the surveillance case 
definition for a patient under investigation for MERS-
CoV infection 
 
 Identify specimens to be obtained and the appropriate 
laboratory test to diagnose a patient with MERS-CoV 
infection 
 
 List infection control measures appropriate for control 
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Objectives 
• Describe the clinical spectrum of disease caused by 
MERS-CoV  
• Identify the key components in the surveillance case 
definition for a patient under investigation for MERS-CoV 
• Identify specimens to be obtained and the appropriate 
laboratory test to diagnose a patient with MERS-CoV 




• Enveloped positive strand RNA virus 
• Human CoVs isolated in the 1960s 







– Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV)  
Coronavirus Classification 
• Alpha 
– Human examples: HCoV-229E, HCoV-NL63  
– Pig, dog, and cat CoVs 
• Beta 
– HCoV-OC43, HCoV-HKU1, HCoV-SARS 
– MHV, rat, pig and cow CoVs 
– MERS-CoV 
• Gamma 
– Chicken and turkey CoVs 
• Delta 
– Bird CoVs 
 
  
Clinical Spectrum of Illness: 
HCoVs: 229E, NL-63, OC-43, HKU1 
• Most often associated with upper 
respiratory tract infections in children 
• Pneumonia and lower tract infections in 
immunocompromised individuals and the 
elderly 
• May play a role in exacerbations of 
underlying respiratory diseases 
 
Epidemiology: HCoVs: 229E, 
NL-63, OC-43, HKU1  
• Worldwide 
• Seasonality: Winter and spring in temperate 
climates 
• Exposure common in early childhood 
• Transmission likely to be droplet, contact, and 
indirect contact 
• Symptoms and viral loads high first few days 
of illness 
• Incubation period 2-5 days 
Clinical Spectrum of Illness: 
SARS 
• Fever, myalgia, headache, chills 1-2d, 
followed by a nonproductive cough and 
shortness of breath 5-7d after onset 
• Most identified illnesses recognized in adults 
• ~25 % diarrhea 
• 20-30% management in ICUs  
– ARDS, mechanical ventilation 
• ~ 10-15 % mortality rate, higher in adults 
>60y 
Epidemiology: SARS 
• First recognized Nov., 2002 as sporadic 
cases in Guandong province, China 
• Outbreak period 2002-2003 
• Hong Kong hotel contributed to spread of 
virus to several countries 
• 8,098 probable SARS cases 
– 774 deaths 
Epidemiology: SARS 
• Incubation period is 2-10d* (median 4d) 
• Transmission through droplets 
– Aerosol spread? 
– Fomites? 
– Fecal- respiratory transmission at an 
apartment complex in Hong Kong 
• Transmission most likely during 2nd 
week of illness 
• Super spreading events 
First Reported MERS-CoV Case 
• 60 year old Saudi man 
• Presented on June 13th with 7d h/o fever and 
cough; recent shortness of breath 
• Increasing blood urea nitrogen (BUN) and 
creatinine, starting day 3 of admission 
• White cell count normal on admission (but 
92.5% neutrophils) and increased to a peak 
of 23,800 cells per cubic millimeter on day 10 
with neutrophilia, lymphopenia, and 
progressive thrombocytopenia 
 
Zaki et al. N Engl J Med 2012 367:1814-20 
 
 
First Case: Chest Radiographs 
A: On admission 
B: 2 days later 
Zaki et al. N Engl J Med 2012 367:1814-20 
Bilateral enhanced pulmonary 
hilar vascular shadows (more 
prominent on the left) and 
accentuated bronchovascular 
lung markings. Multiple patchy 
opacities in middle and lower 
lung fields 
Opacities more 
confluent and dense 
First Case Outcome 
• Patient developed acute respiratory 
distress syndrome (ARDS) and multiorgan 
dysfunction syndrome 
• Died June 24th 
• No close contacts with severe illnesses 
reported  
Zaki et al. N Engl J Med 2012 367:1814-20 
Second Case 
• 49 year old Qatari national 
• Onset of illness September 3rd with mild respiratory 
symptoms 
• September 9th- admission to Qatar hospital with bilateral 
pneumonia- subsequent intubation 
• September 12th admitted to London ICU with respiratory 
failure and renal failure 
• Fully dependent on ECMO 
• History of travel to Saudi Arabia July 31- Aug. 18, where 
noted to have URI symptoms (and traveling companions) 
• History of farm (camels and sheep) exposure, but no 
history of direct contact with these animals 
  
Eurosurv, Vol. 17:40, Oct. 4, 2012 
 
Second Case: Management 
• Airborne precautions 
• Close contacts monitored for at least 10d 
• 64 contacts identified among healthcare 
personnel (HCP), family, and friends 
– No severe acute respiratory illnesses 
identified 
– 13 HCP with mild respiratory symptoms 
– 10  HCP negative for MERS-CoV 
Eurosurv, Vol. 17:40, Oct. 4, 2012 
MERS-CoV: Link 
• Virus from second case compared to virus 
isolated from lung tissue of first case 
• 99.5% identity: One nucleotide mismatch 
over regions (replicase) compared 
• Genome sequence: JX869059.1 
Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) 
de Groot et al.  J Virol.  May, 2013; Epub ahead of print  
Jordan 
cluster 
April, 2012 Sept,, 2012 
Recognition of a 
novel coronavirus, 
Saudi Arabia and 
Qatar 
Nov., 2012 
1st family cluster, 
 Saudi Arabia 
Feb., 2013 
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March, 2013 
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Into Germany 
April, 2013 
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Emergence of a Novel Virus 
Saudi Arabia Household Cluster 
• A cluster of 4 respiratory illnesses in a 
family who lived in an apartment  
– All males; ages 16-70y 
• All hospitalized 
• 3 of 4 confirmed with MERS-CoV 
• 3 of 4 patients with gastrointestinal 
symptoms: diarrhea, abdominal pain, 
anorexia) 
• 2 deaths  
 
Memish ZA et al. NEJM epub May 29, 2013  
 
Saudi Arabia Household Cluster: 
Virus Detection 
• Patient 1: Positive bronchial lavage 
specimen  
• Patients 2 and 4: Sputum positive  
• Patient 3’s illness milder and no lower 
respiratory tract specimens available; 
upper respiratory tract swabs negative 
Memish ZA et al. NEJM epub May 29, 2013  
Memish ZA et 
al. NEJM epub 





healthy as of 
Jan., 2013 
Jordan Cluster, April, 2012 
• 2 confirmed cases reported retrospectively 
• Both cases fatal 
• Occurred at the same time as a cluster of 
severe respiratory illness among 
healthcare workers, N=13 
 














HPA UK Novel Coronavirus Investigation Team; Eurosurv  2013; 18(11) 
Timeline of UK Cluster 
HPA UK Novel Coronavirus Investigation Team; Eurosurv  2013; 18(11) 
UK Cluster: Public Health 
Implications 
• Evidence of person-to-person transmission 
• Coinfection with influenza (index case) and 
parainfluenza type 2 (both secondary 
cases) 
• No sustained chains of transmission 
• Incubation period may be 1-9 days 
HPA UK Novel Coronavirus Investigation Team; Eurosurv  2013; 18(11) 
Nosocomial Transmission in 
France, Index Patient 
• 64 year old man, returned from travel to Dubai 5 days 
earlier 
• History of renal transplantation 
• Onset of symptoms: Diarrhea, fever, chills 
• Abdominal CT showed pulmonary infiltrates 2d after onset 
• Developed cough and dyspnea 4d after onset; initial NP 
swab deemed negative, but bronchoalveolar lavage 
specimen positive  
• Respiratory failure, renal failure- death, 36 days after onset 
of illness 
 
Guery et al. Lancet 2013; epub May 30 
Nosocomial Transmission in 
France, Patient 2 
• 51 year old man with history of myocardial infarction, 
arterial hypertension, and steroid therapy for histamine-
induced angioedema.  Also had history of several 
episodes of deep venous thrombosis 
• Shared a hospital room with index patient during day 4- 
day 7 of index patient’s illness (index patient mostly 
confined to bed, while Patient 2 moved around) 
• Shared bathroom 
• NP swabs inconclusive; induced sputum positive for 
MERS-CoV 
• No aerosolizing procedures performed for index patient 
• No suspicion of MERS-CoV 
Guery et al. Lancet 2013; epub May 30 
Radiographs of Patient 2 
Guery et al. Lancet 2013; epub May 30 
 
A. Consolidation of 
right upper lobe, 1 
day after onset of 
illness 
B. 4 days after 




left lower lobe 
C and D. Bilateral ground-
glass opacities and 
consolidation, 7 days and 
9 days after onset of 
illness, respectively 
Timeline of French Cluster 
Guery et al. Lancet 2013; epub May 30 
French Cluster: Public Health 
Implications 
• Nosocomial transmission 
• Initial presentation without respiratory 
symptoms 
• Incubation period up to 9-12 days 
• Lower respiratory tract specimens may be 
preferred samples for detection of MERS-
CoV 
 
Guery et al. Lancet 2013; epub May 30 
MERS-CoV Outbreak in Saudi Arabia  
April – May 2013 
• Al-Ahsa governorate in eastern region 
• Cluster currently being investigated 
• 25 confirmed cases, 14 confirmed deaths 
• 18 males, 7 females; Ages 14 - 94 years, median age: 58 
• Initial cases associated with one hospital but now also: 
– Family contacts 
– Healthcare workers 
– Cases with no link to hospital 
• Most cases with comorbidities  
 
MERS-CoV- Overall Epidemiology 
• Approximately 50% mortality rate 
• Onsets between April 2012 and May 29, 2013 
• Median age ~ 56 y 
– 2 pediatric cases reported 
• Male predominance 
• Most cases reported with comorbidities 
• Cases by country of residence:   
– Saudi Arabia 40, UK 3, Jordan 2, Qatar 2, UAE 1, France 2, 
Tunisia 2, Italy 3   
– Three were returning travelers, 3 medical transfers 
Confirmed cases of MERS-CoV (n=55) and 
history of travel from the Arabian Peninsula 
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 ¶ ** 
CDC Case Definition: Surveillance 
• A Patient Under Investigation (PUI) is a person with- 
– an acute respiratory infection, which may include fever (≥ 
38°C , 100.4°F) and cough; AND 
– suspicion of pulmonary parenchymal disease (e.g., 
pneumonia or acute respiratory distress syndrome based on 
clinical or radiological evidence of consolidation); AND 
– history of travel from the Arabian Peninsula or neighboring 
countries within 14 days; AND 
– not already explained by any other infection or etiology, 
including all clinically indicated tests for community-acquired 
pneumonia according to local management guidelines.  
 
CDC Case Definition: Surveillance 
• Persons who develop severe acute lower respiratory illness of 
known etiology within 14 days after travel from the Arabian 
Peninsula or neighboring countries but do not respond to 
appropriate therapy; OR 
 
• Persons who develop severe acute lower respiratory illness who 
are close contacts of a symptomatic traveler who developed 
fever and acute respiratory illness within 14 days after travel 
from the Arabian Peninsula or neighboring countries. Close 
contact is defined as providing care for the ill traveler (e.g., a 
healthcare worker or family member), or having similar close 
physical contact; or stayed at the same place (e.g. lived with, 
visited) as the traveler while the traveler was ill. 
 
CDC Case Definition: Close 
Contact 
• Close contact is defined as: 
– Any person who provided care for the patient, 
including a healthcare worker or family 
member, or had similarly close physical 
contact. 
– Any person who stayed at the same place 
(e.g. lived with, visited) as the patient while 
the patient was ill. 
 
CDC Case Definitions: 
Probable Case 
• Any person who- 
– meets the criteria above for “Patient Under Investigation” and has clinical, radiological, 
or histopathological evidence of pulmonary parenchyma disease (e.g. pneumonia or 
ARDS), but no possibility of laboratory confirmation exists, either because the patient 
or samples are not available or there is no testing available for other respiratory 
infections, AND  
– is a close contact with a laboratory-confirmed case, AND 
– has illness not already explained by any other infection or etiology, including all 
clinically indicated tests for community-acquired pneumonia according to local 
management guidelines. 
• OR any person with-  
– severe acute respiratory illness with no known etiology, AND  
– an epidemiologic link to a confirmed MERS case. 
 
Confirmed Case 
• A person with laboratory confirmation of infection with MERS-CoV. 
 

Interim Infection Prevention and Control 
Recommendations for Hospitalized Patients  
• Standard, contact, and airborne precautions are 
recommended for management of hospitalized 
patients with known or suspected MERS-CoV 
infection  
• These recommendations are consistent with 
those recommended for the coronavirus that 
caused severe acute respiratory syndrome 
(SARS) 
• As information becomes available, these 
recommendations will be re-evaluated and 
updated as needed 
 
Infection Control Recommendations for 
Hospitalized Patients 
• These recommendations are for hospitalized 
patients who meet the case definition and are based 
on the following issues: 
– Poorly characterized clinical signs and symptoms, 
and a suspected high rate of morbidity and 
mortality among infected patients 
– Unknown modes of transmission of MERS-CoV 
– Lack of a vaccine and chemoprophylaxis 
– Evidence of limited, not sustained, human-to-
human transmission 
– Absence of confirmed or probable MERS-CoV 
cases in the United States 
 
Patient Placement 
• Airborne Infection Isolation Room (AIIR) 
– If an AIIR is not available, the patient should be 
transferred as soon as is feasible to a facility where 
an AIIR is available.  
– Pending transfer, place a facemask on the patient 
and isolate him/her in a single-patient room with the 
door closed.  
– The patient should not be placed in any room 
where room exhaust is recirculated without high-
efficiency particulate air (HEPA) filtration. 
• Once in an AIIR, the patient’s facemask may be 
removed. 
• When outside of the AIIR, patients should wear a 





• Limit transport and movement of the patient 
outside of the AIIR to medically-essential 
purposes. 
• Implement staffing policies to minimize the 
number of personnel who must enter the room.  
Personal Protective Equipment (PPE) for 
Healthcare Personnel (HCP) 
• Gloves 
• Gowns 
• Eye protection (goggles or face shield) 
• Respiratory protection that is at least as 
protective as a fit-tested NIOSH-certified 
disposable N95 filtering facepiece respirator  
 
Personal Protective Equipment (PPE) for 
Healthcare personnel (HCP) 
• Recommended PPE should be worn by HCP 
upon entry into patient rooms or care areas. 
• Upon exit from the patient room or care area, 
PPE should be removed and either: 
– Discarded, or  
– For re-useable PPE, cleaned and disinfected 
according to the manufacturer’s reprocessing 
instructions. 
Environmental Infection Control 
• Follow standard procedures, per hospital policy 
and manufacturers’ instructions, for cleaning 
and/or disinfection of: 
– Environmental surfaces and equipment  
– Textiles and laundry 
– Food utensils and dishware 
 
Laboratory Testing 
• Lower respiratory specimens (sputum, 
bronchoalveolar lavage, endotracheal) are 
a priority respiratory specimen for real time 
reverse transcription polymerase chain 
reaction (RT-PCR) testing 
• Respiratory (lower and upper tracts), stool, 
and serum specimens 
• Specimen collection at different times 
 
Emergency Use Authorization 
• FDA issued an EUA on June 5, 2013, to authorize 
use of CDC's “Novel coronavirus 2012 real-time 
reverse transcription–PCR assay” to test for MERS-
CoV in clinical respiratory, blood, and stool 
specimens.  
 
• Assay will be deployed to Laboratory Response 
Network (LRN) laboratories in all 50 states over the 
coming weeks.  
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Courtesy of Dean Erdman 
CS Goldsmith, MG Metcalfe, A Tamin 
CS Goldsmith, MG Metcalfe, A Tamin 
Approach to Serology 
• Identify and generate candidate CoV  
antigens  
– Using proteins from similar bat viruses 
• Develop ELISA-based assay 
• Evaluate assay with an extensive panel 




Location of Bat Sampling Sites 
A- Ghana 
B- Europe 
Annan et al.  Emerg Infect Dis 2013 , 19:456-59 
Therapeutics 
• No vaccines developed as of yet 
• No antivirals identified as of yet 
• Treatment is supportive 
 
 
MERS-CoV Snapshot: June, 2013 
• May cause mild to severe illness 
• Evidence of person-to-person transmission 
• Nosocomial spread with healthcare personnel 
transmission 
• Focus in the Arabian Peninsula 
• ~ 50% mortality rate 
• No cases identified in the U.S. 
Conclusions: 
• MERS-CoV is a different virus than 
SARS-CoV, but also virulent 
• More reported cases in past 2 months 
• Persons with underlying health 
conditions at increased risk of severe 
disease 





MERS Coronavirus Issues 
• Human surveillance for additional cases 
– Laboratory diagnostics 
– Surveillance for severe acute respiratory infections 
• Need for more investigations to understand human-
to- human routes of exposure 
• Animal surveillance 
• Geography 
• Management of patients under investigation 
– Rule out other etiologies 
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Join Us on Facebook 
 CDC Facebook page for 
Health Partners! “Like” our 
page today to receive COCA 
updates, guidance, and 
situational awareness about 
preparing for and responding 
to public health emergencies.  
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